INGN Stock Recent News
INGN LATEST HEADLINES
Inogen's overall first-quarter 2025 results continue to gain from higher business-to-business sales.
Inogen, Inc. (NASDAQ:INGN ) Q1 2025 Earnings Conference Call May 7, 2025 5:00 PM ET Company Participants Ryan Peterson - Investor Relations Kevin Smith - President and CEO Mike Bourque - CFO Conference Call Participants Colin Clark - Stifel Mike Matteson - Needham & Company Margaret Andrew - William Blair Operator Welcome to Inogen's First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Inogen (INGN) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.62 per share a year ago.
The medical device sector saw steady sales growth in the first quarter of 2025, supported by innovation in AI, wearables, and personalized care. However, earnings gains were more modest as global tariffs, inflationary costs, and supply chain disruptions continued to pressure margins.
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen To Present at 24th Annual Needham Virtual Healthcare Conference.
Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Inogen, Inc. INGN is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid fourth-quarter 2024 performance and a strong product portfolio, seems justified.
Inogen's new management and strategy are yielding results, with better-than-expected 2024 performance and a more stable base from which to keep growing the B2B business. Despite weak DTC sales, strong B2B growth drove better-than-expected sales in Q4, and Inogen likewise beat on margins. Guidance disappointed investors and prompted a 15% drop in the shares, as moderately better revenue guidance was offset by unexpected gross margin deleverage.